July 2, 2022 | Targeted Therapies in Oncology

ADC/ICI Combo Effective in BCG-Unresponsive NMIBC

July 28, 2022

Clinical Articles

Results from a phase 3 study of pembrolizumab and nadofaragene firadenovec in patients with BCG-unresponsive non–muscle invasive bladder cancer suggests that immune checkpoint inhibitors have synergy with antibody drug conjugates.

Exploring the Role of Gut Microbiome in Cancer Therapy

July 26, 2022

Clinical Articles

The normal gut microbiota metabolizes nutrients and drugs, maintains the gut mucosal barrier integrity, protects against pathogens, and trains and develops the immune system. The gut microbiome has been implicated in many human pathologies.

Promising Findings From DESTINY-Breast04 Trial Energizes ASCO Meeting

July 22, 2022

Clinical Articles

Harnessing existing and otherwise safe antibody-targeting strategies and combining them with chemotherapy or other bioactive compounds or as a bispecific dual antibody moiety are an exciting strategy of protein engineering that is emerging and coming into its own in oncology.